Three insights:
1. Kuros will determine the use of Fibrin-PTH in single level transforaminal lumbar interbody fusion procedures in patients with degenerative disc disease, with autograft as the comparator.
2. Fibrin-PTH consists of a natural fibrin-based healing matrix with an immobilized targeted bone growth factor and is designed to apply onto and around an intervertebral body fusion device as a gel.
3. The primary endpoint of the trial is radiographic interbody fusion, using CT-scans at 12 months.
More articles on devices:
NASS unveils ’20 Under 40′ spine surgeons for 2019
Dr. Death to hit TV screens: A timeline of the former neurosurgeon’s case
How spine, neurosurgery departments are evolving — key thoughts from 4 leaders
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
